Last reviewed · How we verify
NCT03332264: SPORTS
Sequent Please Drug Coated Balloons Versus Primary Stent Application in Long SFA Lesions
NA trial testing SeQuent Please OTW in Stenosis in 224 participants. Completed in 12 December 2023.
31 January 2022
Quick facts
| Lead sponsor | InnoRa GmbH |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 224 |
| Start date | 30 March 2017 |
| Primary completion | 31 January 2022 |
| Estimated completion | 12 December 2023 |
| Sites | 10 locations across Austria, Germany |
Drugs / interventions tested
- SeQuent Please OTW
- Eluvia Vascular Stent System
- Nitinol stent
Conditions studied
- Stenosis — all drugs for Stenosis →
- Occlusion — all drugs for Occlusion →
- Restenosis — all drugs for Restenosis →
Sponsor
InnoRa GmbH
Who can join
18 and older, any sex, with Stenosis or Occlusion. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Patients with peripheral artery disease will be treated with either drug coated balloon catheter, drug coated stent or uncoated stent.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
State-of-the-Art Definitive Femoropopliteal Lesion Treatment: A Case-Based Systematic Approach.
Korosoglou G, Malyar N, Schmidt A, Lichtenberg M, et al · · 2026 · PMID 42041976 · DOI 10.3390/jcdd13040150
Verify or expand the search:
- PubMed search for NCT03332264
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Stenosis
Currently open trials in the same condition.
- NCT07073612 — Transcatheter Fontan Stenting: Impact on Hepatic Stiffness and Exercise Capacity · recruiting
- NCT06986954 — Beacon Tip Sizing Catheter and Slip-Cath Beacon Tip Catheter Study · recruiting
- NCT06539689 — A Trail of Sperstent® Used for Residual Lesions of Femoropopliteal Arteries · NA · recruiting
- NCT05692024 — COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER · Phase 1, PHASE2 · recruiting
- NCT06255769 — Diagnosis of Myocardial Ischemia With MCG Using SPECT as a Reference Standard · recruiting
Other InnoRa GmbH trials
Trials by the same sponsor.
- NCT05445258 — Safety and Tolerance of the Use of InnoCath AB® Hyper-compliant Balloon · NA · terminated
- NCT03908450 — Treatment of Coronary De-novo Stenosis by a Sirolimus Coated Balloon or a Paclitaxel Coated Balloon Catheter · NA · completed
- NCT04017364 — Treatment of Coronary De-novo Stenosis by a Sirolimus Coated Balloon or a Paclitaxel Coated Balloon Catheter Malaysia · NA · completed
- NCT03242096 — Treatment of Coronary In-stent Restenosis (ISR) by a Sirolimus Coated or a Paclitaxel Coated Balloon · NA · completed
- NCT02996318 — Treatment of Coronary In-Stent Restenosis by a Sirolimus (Rapamycin) Coated Balloon or a Paclitaxel Coated Balloon · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03332264 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by InnoRa GmbH
- Last refreshed: 15 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03332264.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing